

# Jia-Lin Yang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7682269/publications.pdf>

Version: 2024-02-01

60  
papers

1,877  
citations

236833

25  
h-index

265120

42  
g-index

61  
all docs

61  
docs citations

61  
times ranked

3299  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of morphology and collagen-functionalization on the redox equilibria of nanoceria for cancer therapies. <i>Materials Science and Engineering C</i> , 2021, 120, 111663.	3.8	4
2	Preclinical Cancer Theranosticsâ€”From Nanomaterials to Clinic: The Missing Link. <i>Advanced Functional Materials</i> , 2021, 31, 2104199.	7.8	33
3	Geometric regulation of histone state directs melanoma reprogramming. <i>Communications Biology</i> , 2020, 3, 341.	2.0	19
4	The synergistic inhibitory effect of combining therapies targeting EGFR and mitochondria in sarcomas. <i>Oncotarget</i> , 2020, 11, 46-61.	0.8	1
5	Engineering oxygen vacancies through construction of morphology maps for bio-responsive nanoceria for osteosarcoma therapy. <i>CrystEngComm</i> , 2018, 20, 1536-1545.	1.3	25
6	Using Career Development Learning in Science and Information Technology Courses to Build 21st-Century Learners. <i>Journal of Continuing Higher Education</i> , 2018, 66, 137-145.	0.6	2
7	Antitumour effects and mechanisms of action of the panHER inhibitor, dacomitinib, alone and in combination with the STAT3 inhibitor, S3I-201, in human sarcoma cell lines. <i>International Journal of Oncology</i> , 2018, 52, 2143-2154.	1.4	6
8	Significance of Phosphorylated Epidermal Growth Factor Receptor and Its Signal Transducers in Human Soft Tissue Sarcoma. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1159.	1.8	15
9	Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring &lt;em>EGFR&lt;/em> mutations: a review of the evidence. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 5461-5473.	1.0	41
10	Regulatory roles and therapeutic potential of microRNA in sarcoma. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 118-130.	2.0	17
11	Nanoparticle-siRNA: A potential cancer therapy?. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 159-169.	2.0	130
12	Safety and accuracy of core biopsy in retroperitoneal sarcomas. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, e174-8.	0.7	16
13	A Microscopic and Biomarker Evaluation of Embolic Filter Debris Collected During Carotid Artery Stenting. <i>Journal of Endovascular Therapy</i> , 2016, 23, 275-284.	0.8	10
14	Overcoming resistance of targeted EGFR monotherapy by inhibition of STAT3 escape pathway in soft tissue sarcoma. <i>Oncotarget</i> , 2016, 7, 21496-21509.	0.8	20
15	Targeting the PI3K/PTEN/AKT/mTOR Pathway in Treatment of Sarcoma Cell Lines. <i>Anticancer Research</i> , 2016, 36, 5765-5772.	0.5	23
16	The Potential of panHER Inhibition in Cancer. <i>Frontiers in Oncology</i> , 2015, 5, 2.	1.3	33
17	An Endovascular-First Approach to the Treatment of Critical Limb Ischemia Results in Superior Limb Salvage Rates. <i>Journal of Endovascular Therapy</i> , 2015, 22, 473-481.	0.8	32
18	Carbon-Coated Gold Nanorods: A Facile Route to Biocompatible Materials for Photothermal Applications. <i>ACS Applied Materials &amp; Interfaces</i> , 2015, 7, 25658-25668.	4.0	51

#	ARTICLE	IF	CITATIONS
19	Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 671-689.	1.2	132
20	Impact of STAT3 inhibition on survival of osteosarcoma cell lines. <i>Anticancer Research</i> , 2014, 34, 6537-45.	0.5	15
21	Uncovering a key to the process of metastasis in human cancers: a review of critical regulators of anoikis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1795-1805.	1.2	53
22	Targeted therapy in soft tissue sarcoma-a novel direction in therapeutics. <i>Chinese Clinical Oncology</i> , 2013, 2, 22.	0.4	2
23	<b>Adjunctive Ultrasonography to Minimize Iodinated Contrast Administration During Carotid Artery Stenting:</b>A Randomized Trial. <i>Journal of Endovascular Therapy</i> , 2012, 19, 638-647.	0.8	11
24	Molecular targeted therapies for cancer: Sorafenib mono-therapy and its combination with other therapies (Review). <i>Oncology Reports</i> , 2012, 27, 1303-11.	1.2	77
25	STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers. <i>International Journal of Oncology</i> , 2012, 41, 1181-1191.	1.4	172
26	An Arteriovenous Fistula Model of Intimal Hyperplasia for Evaluation of a Nitinol U-Clip Anastomosis. <i>European Journal of Vascular and Endovascular Surgery</i> , 2012, 43, 224-231.	0.8	10
27	IGF1R-Targeted Therapy and Its Enhancement of Doxorubicin Chemosensitivity in Human Osteosarcoma Cell Lines. <i>Cancer Investigation</i> , 2011, 29, 521-532.	0.6	29
28	microRNA-34 family and treatment of cancers with mutant or wild-type p53 (Review). <i>International Journal of Oncology</i> , 2011, 38, 1189-95.	1.4	45
29	Effect of type 1 insulin-like growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involved. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 639-650.	1.2	22
30	Diagnosis of second head and neck tumors in primary laryngeal SCC is an indicator of overall survival and not associated with poorer overall survival: A single centre study in 987 patients. <i>Journal of Surgical Oncology</i> , 2010, 101, 72-77.	0.8	15
31	Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 1137-1148.	1.2	39
32	Mutant p53 and cyclin A1 protein expression in primary laryngeal squamous cell carcinomas do not correlate to second primary tumours of the head and neck*. <i>ANZ Journal of Surgery</i> , 2009, 79, 48-54.	0.3	9
33	Protein Expression of Epidermal Growth Factor Receptor in Laryngeal Squamous Cell Carcinoma Index Tumors Correlates with Diagnosis of Second Primary Tumors of the Upper Aero-Digestive Tract. <i>Annals of Surgical Oncology</i> , 2009, 16, 2888-2894.	0.7	11
34	Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency. <i>International Journal of Cancer</i> , 2008, 123, 258-263.	2.3	10
35	IGF1R targeted therapy in human osteosarcoma cell lines. <i>Bone</i> , 2008, 43, S111.	1.4	0
36	BMP-7 and CBFA1 in allograft bonein vivo bone formation and the influence of $\beta^3$ -irradiation. <i>Journal of Biomedical Materials Research - Part A</i> , 2007, 80A, 435-443.	2.1	16

#	ARTICLE	IF	CITATIONS
37	Targeted therapies in adult soft tissue sarcomas. <i>Journal of Surgical Oncology</i> , 2007, 95, 183-184.	0.8	12
38	Erlotinib (OSI-774)-induced inhibition of transitional cell carcinoma of bladder cell line growth is enhanced by interferon- $\gamma$ . <i>BJU International</i> , 2007, 99, 1539-1545.	1.3	15
39	Expression of HER1/EGFR protein in human soft tissue sarcomas. <i>European Journal of Surgical Oncology</i> , 2006, 32, 466-468.	0.5	33
40	Interferon- $\gamma$ Promotes the Anti-Proliferative Effect of Gefitinib (ZD1839) on Human Colon Cancer Cell Lines. <i>Oncology</i> , 2005, 69, 224-238.	0.9	15
41	Interferon-alpha promotes the anti-proliferative effect of Erlotinib (OSI-774) on human colon cancer cell lines. <i>Cancer Letters</i> , 2005, 225, 61-74.	3.2	13
42	Preoperative Chemoradiotherapy (Modified Eilber Protocol) Provides Maximum Local Control and Minimal Morbidity in Patients With Soft Tissue Sarcoma. <i>Annals of Surgical Oncology</i> , 2005, 12, 646-653.	0.7	64
43	Expression of insulin-like growth factor mitogenic signals in adult soft-tissue sarcomas: significant correlation with malignant potential. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2004, 444, 142-148.	1.4	15
44	Differential expression of osteogenic factors associated with osteoinductivity of human osteosarcoma cell lines. <i>Journal of Biomedical Materials Research Part B</i> , 2004, 70A, 122-128.	3.0	26
45	CHANGES IN EPIDERMAL GROWTH FACTOR RECEPTOR EXPRESSION IN HUMAN BLADDER CANCER CELL LINES FOLLOWING INTERFERON- $\gamma$ TREATMENT. <i>Journal of Urology</i> , 2004, 172, 733-738.	0.2	37
46	Down-regulation of KAI1/CD82 protein expression in oral cancer correlates with reduced disease free survival and overall patient survival. <i>Cancer Letters</i> , 2004, 213, 91-98.	3.2	31
47	Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. <i>Journal of Surgical Oncology</i> , 2003, 82, 184-193.	0.8	66
48	TGF- $\beta$ 2, BMPs, and their signal transducing mediators, Smads, in rat fracture healing. <i>Journal of Biomedical Materials Research Part B</i> , 2002, 60, 392-397.	3.0	76
49	Wound healing and growth factor expression in T lymphocyte deficiency. <i>ANZ Journal of Surgery</i> , 2002, 72, 491-495.	0.3	8
50	Expression of the KAI1 metastasis suppressor gene in non-metastatic versus metastatic human colorectal cancer. <i>Anticancer Research</i> , 2002, 22, 3337-42.	0.5	7
51	Effect of nifedipine in metastatic colon cancer with DNA mismatch repair gene defect. <i>Lancet, The</i> , 2001, 357, 1767-1768.	6.3	16
52	Genetic Markers of Survival and Liver Recurrence after Resection of Liver Metastases from Colorectal Cancer. <i>World Journal of Surgery</i> , 2001, 25, 996-1001.	0.8	33
53	Genomic alterations (LOH, MI) on chromosome 17q21-23 and prognosis of sporadic colorectal cancer. <i>International Journal of Cancer</i> , 2000, 89, 1-7.	2.3	30
54	Evidence for post-transcriptional down-regulation of the apoptosis-related gene bcl-2 in human colorectal cancer. , 2000, 191, 15-20.		14

#	ARTICLE	IF	CITATIONS
55	Urokinase-type plasminogen activator and its receptor in colorectal cancer: Independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets. <i>International Journal of Cancer</i> , 2000, 89, 431-439.	2.3	108
56	Protein Markers in Colorectal Cancer. <i>Annals of Surgery</i> , 1999, 230, 179.	2.1	40
57	Overexpression of nm23 Protein Assessed by Color Video Image Analysis in Metastatic Colorectal Cancer: Correlation with Reduced Patient Survival. <i>World Journal of Surgery</i> , 1998, 22, 484-490.	0.8	22
58	DNA-Flow Cytometric Analysis of Bladder TCC Using Paraffin-Embedded Tissues. <i>Urologia Internationalis</i> , 1998, 60, 208-215.	0.6	2
59	Higher expression of oncoproteins c-myc, c-erbB-2/neu, PCNA, and p53 in metastasizing colorectal cancer than in nonmetastasizing tumors. <i>Annals of Surgical Oncology</i> , 1996, 3, 574-579.	0.7	44
60	DNA flow-cytometric analysis in colorectal cancer: A comparison of metastasizing and non-metastasizing tumours. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1996, 11, 319-324.	1.4	4